EUVIMEDEUVIMED entdecken
Crossref

Transcaval embolisation of type-II endoleaks – The Australian experience

Kevin Tian iD, Vimalin Samuel, David Sun, Dylan Morris, Yew Toh Wong iD, Ramesh Velu

Vascular · 2026

DOI: 10.1177/17085381241313251 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vascular, 2026. Verfasst von Kevin Tian und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular and Endovascular Surgery, Townsville University Hospital, Townsville, QLD, Australia. Hauptthemen laut MEDLINE: Endoleak, Aortic Aneurysm, Abdominal, Embolization, Therapeutic, Endovascular Procedures. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Embolizing an abdominal aortic aneurysm sac through a transcaval approach is a novel approach to treat type-II endoleaks that occur following aortic endografting. This study reviews the outcomes of this treatment in one of the few centres in Australia that offers this procedure.

Methods

A retrospective cohort study was conducted, including patients who had received transcaval embolisation of type-II endoleak over a 9-year period. The primary outcome was clinical success, defined as the absence of endoleak on post-procedural ultrasonography at 6-weeks, provided the procedure was successfully completed. Other outcomes included clinical success at 1-year, aneurysm size, rupture and aneurysm-related mortality.

Results

Twelve patients with type-II endoleak and AAA sac growth received transcaval embolisation. Technical success was achieved in 91.7% of cases, in which both Onyx 34 and coils were deployed into the sac. Clinical success, defined as an absence of endoleak on ultrasonography 6-weeks after a technically successful procedure, was achieved in 66.7% of patients, none of whom had evidence of endoleak at 1-year post-procedure. In patients whom clinical success was achieved, there was a decrease in sac size during follow-up, from 72.5 ± 13.1 at 6-weeks to 66.0 ± 12.1 at 1-year post-procedure. Aneurysm sac size continued to enlarge if clinical success was not observed, with an average sac size of 72.0 ± 14.1 at 6-weeks increasing to 76.9 ± 15.2 at 1-year. No patients suffered AAA rupture or AAA-related mortality during follow-up.

Conclusions

This study reports a high technical and clinical success rate, with outcomes that could suggest that this procedure could induce sac regression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EndoleakAortic Aneurysm, AbdominalEmbolization, TherapeuticEndovascular ProceduresBlood Vessel Prosthesis ImplantationPolyvinylsHumansRetrospective StudiesTreatment OutcomeMaleAgedFemaleTime FactorsAged, 80 and overAustraliaMiddle AgedAortographyDimethyl Sulfoxide

Stichwörter der Autor:innen

EVAREndoleakendovasculartranscaval

Substanzen

PolyvinylsOnyx copolymerDimethyl Sulfoxide

Autor:innen und Institutionen

  • Department of Vascular and Endovascular Surgery, Townsville University Hospital, Townsville, QLD, Australia.
  • College of Medicine and Dentistry, James Cook University, Townsville, QLD, Australia.

ORCID-Profile: Kevin Tian, Yew Toh Wong

Zitieren

APA

Tian, K., Samuel, V., Sun, D., Morris, D., Wong, Y. T., & Velu, R. (2026). Transcaval embolisation of type-II endoleaks – The Australian experience. Vascular. https://doi.org/10.1177/17085381241313251

Vancouver

Tian K, Samuel V, Sun D, Morris D, Wong YT, Velu R. Transcaval embolisation of type-II endoleaks – The Australian experience. Vascular. 2026. doi:10.1177/17085381241313251

BibTeX
@article{Tian2026,
  author = {Tian, Kevin and Samuel, Vimalin and Sun, David and Morris, Dylan and Wong, Yew Toh and Velu, Ramesh},
  title = {Transcaval embolisation of type-II endoleaks – The Australian experience},
  journal = {Vascular},
  year = {2026},
  doi = {10.1177/17085381241313251}
}
Kostenlos starten →